CDK2 and plasma cell myeloma: ,53,54,55,56 SNS-032 is a CDK inhibitor targeting CDK2, 7 and 957,58 that exerts several anti-cancer effects, including reducing cell growth, inducing apoptosis, and inhibiting angiogenesis and invasion in various cancer types, including esophageal cancer, AML, breast cancer, and multiple myeloma.59